Skip to main content
News > News > The Economics of Reproducibility in Preclinical Research

The Economics of Reproducibility in Preclinical Research

Abstract

Low reproducibility rates within life science research undermine cumulative knowledge production and contribute to both delays and costs of therapeutic drug development. An analysis of past studies indicates that the cumulative (total) prevalence of irreproducible preclinical research exceeds 50%, resulting in approximately US$28,000,000,000 (US$28B)/year spent on preclinical research that is not reproducible—in the United States alone. We outline a framework for solutions and a plan for long-term improvements in reproducibility rates that will help to accelerate the discovery of life-saving therapies and cures.

Freedman, L.P., Cockburn, I.M., Simcoe, T.S., June 9, 2015, DOI: 10.1371/journal.pbio.1002165, accessed at http://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.1002165, 24 January 2016.

Our Effort

Open Therapeutics is a major backer of open science and open access efforts.

Open Therapeutics freely provides to science, technology, engineering, and math (STEM) scientists, or another other seriously interested persons, intellectual properties (patents, etc.), grant funding, lab equipment, document development tools, and preprint server in a collaboration platform (Therapoid™).

When the researchers advance the intellectual properties, s/he gains ScienceCoins™; a blockchain-based cryptocurrency.